Varma Mutual Pension Insurance Co Grows Stake in Vertex Pharmaceuticals Incorporated $VRTX

Key Points

• Varma Mutual Pension Insurance Co increased its stake in Vertex by 16.3%, acquiring 5,700 shares to hold 40,626 shares worth about $18.42 million at the end of the quarter.
• Q1 results beat: Vertex reported $4.47 EPS versus $4.24 expected and revenue of $2.99B (roughly in line), with management reiterating full‑year revenue guidance near ~$13.0B as growth was supported by new product launches beyond cystic fibrosis.
• Insider selling and analyst stance: Insiders sold 80,431 shares (~$37.9M) in the past 90 days, while analysts rate the stock a "Moderate Buy" on average with a $554.83 price target.

Varma Mutual Pension Insurance Co grew its holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX - Free Report) by 16.3% in the 4th quarter, according to the company in its most recent filing with the SEC. The firm owned 40,626 shares of the pharmaceutical company's stock after buying an additional 5,700 shares during the quarter. Varma Mutual Pension Insurance Co's holdings in Vertex Pharmaceuticals were worth $18,418,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also bought and sold shares of the company. Mitsubishi UFJ Asset Management Co. Ltd. lifted its holdings in shares of Vertex Pharmaceuticals by 3.8% in the third quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 544,978 shares of the pharmaceutical company's stock valued at $213,435,000 after purchasing an additional 20,053 shares in the last quarter. Danske Bank A S bought a new stake in Vertex Pharmaceuticals during the third quarter worth about $64,417,000. Leuthold Group LLC bought a new stake in Vertex Pharmaceuticals during the third quarter worth about $5,030,000. Legacy Capital Group California Inc. bought a new stake in Vertex Pharmaceuticals during the third quarter worth about $956,000. Finally, Advisory Resource Group bought a new stake in Vertex Pharmaceuticals during the third quarter worth about $1,286,000. Hedge funds and other institutional investors own 90.96% of the company's stock.

Vertex Pharmaceuticals Stock Performance

NASDAQ VRTX opened at $429.85 on Tuesday. The stock has a market cap of $109.34 billion, a PE ratio of 28.04, a P/E/G ratio of 1.84 and a beta of 0.30. The firm has a 50-day moving average of $453.82 and a 200-day moving average of $449.48. Vertex Pharmaceuticals Incorporated has a 52-week low of $362.50 and a 52-week high of $507.92.

Vertex Pharmaceuticals (NASDAQ:VRTX - Get Free Report) last announced its quarterly earnings results on Monday, May 4th. The pharmaceutical company reported $4.47 EPS for the quarter, beating analysts' consensus estimates of $4.24 by $0.23. The business had revenue of $2.99 billion for the quarter, compared to analyst estimates of $2.99 billion. Vertex Pharmaceuticals had a net margin of 32.94% and a return on equity of 24.30%. Vertex Pharmaceuticals's quarterly revenue was up 8.3% on a year-over-year basis. During the same quarter in the prior year, the business earned $4.06 EPS. As a group, analysts predict that Vertex Pharmaceuticals Incorporated will post 16.81 EPS for the current fiscal year.

More Vertex Pharmaceuticals News

Here are the key news stories impacting Vertex Pharmaceuticals this week:

• Positive Sentiment: Q1 adjusted EPS beat expectations ($4.47 vs. ~$4.24) and net margin/ROE remained strong; management reiterated full‑year revenue guidance near the street (~$13.0B). Business Wire: Q1 Results
• Positive Sentiment: Sales growth was driven by new disease‑area franchises — management said KASJEVY and GERNAVICS (and other recent launches) accounted for a sizeable portion of product growth, signaling diversification beyond cystic fibrosis. Fool: Earnings Call Highlights
• Positive Sentiment: Regulatory progress continues to expand the CF franchise (FDA expanded ALYFTREK to younger patients), supporting the durable cash flow base that funds R&D and launches. Yahoo: FDA ALYFTREK Expansion
• Neutral Sentiment: Company hosted an earnings call / transcript is available — useful for investors wanting management detail on product uptake, pipeline timing and guidance assumptions. Seeking Alpha: Call Transcript
• Neutral Sentiment: Street reaction is mixed but not overwhelming; company kept FY outlook essentially unchanged (guidance ~ $13.0–13.1B), which many view as confirmation rather than an upgrade. Yahoo: Sales Beat / Guidance
• Negative Sentiment: Market reaction turned negative after some outlets flagged mixed details: third‑party data noted revenue/EPS discrepancies vs. certain estimates, operating cash flow fell and capex rose sharply, and notable insider sales were highlighted — these factors pressured the stock. QuiverQuant: Stock Falls on Q1
• Negative Sentiment: Some headlines described the report as “mixed” (revenue roughly in‑line but not a clear beat in all feeds), which can trigger short‑term selling even with solid fundamentals. Yahoo: Vertex Dips on Mixed Report

Insider Activity at Vertex Pharmaceuticals

In other Vertex Pharmaceuticals news, EVP Amit Sachdev sold 58,613 shares of the company's stock in a transaction on Thursday, February 19th. The stock was sold at an average price of $468.83, for a total value of $27,479,532.79. Following the transaction, the executive vice president directly owned 58,934 shares of the company's stock, valued at $27,630,027.22. This represents a 49.86% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, EVP Duncan Mckechnie sold 4,910 shares of the company's stock in a transaction on Wednesday, February 25th. The shares were sold at an average price of $487.65, for a total value of $2,394,361.50. Following the completion of the transaction, the executive vice president directly owned 17,559 shares in the company, valued at approximately $8,562,646.35. This represents a 21.85% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 80,431 shares of company stock valued at $37,875,167 in the last 90 days. Corporate insiders own 0.20% of the company's stock.

Analyst Ratings Changes

VRTX has been the topic of several analyst reports. Jefferies Financial Group initiated coverage on Vertex Pharmaceuticals in a report on Tuesday, March 10th. They set a "buy" rating and a $580.00 target price on the stock. Citigroup upped their target price on Vertex Pharmaceuticals from $575.00 to $585.00 and gave the stock a "buy" rating in a report on Tuesday, March 10th. Wall Street Zen lowered Vertex Pharmaceuticals from a "buy" rating to a "hold" rating in a report on Saturday. Evercore upped their price objective on Vertex Pharmaceuticals from $475.00 to $530.00 and gave the company an "outperform" rating in a research note on Friday, January 23rd. Finally, UBS Group raised their price objective on Vertex Pharmaceuticals from $535.00 to $545.00 and gave the company a "buy" rating in a research report on Monday, January 26th. One research analyst has rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating and six have given a Hold rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average price target of $554.83.

Vertex Pharmaceuticals Profile

Vertex Pharmaceuticals Inc is a Boston-based biotechnology company focused on the discovery, development and commercialization of therapies for serious diseases. Founded in 1989, Vertex built its reputation on research-driven drug development and is best known for its work in cystic fibrosis (CF), where its portfolio of small-molecule CFTR modulators transformed standards of care for many people with the disease. The company operates research and development, manufacturing and commercial organizations and serves patients and healthcare systems in multiple international markets.

Vertex's marketed products center on CFTR modulators that target the underlying cause of cystic fibrosis rather than just treating symptoms.

Want to see what other hedge funds are holding VRTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.